



July 10, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2017-002047-15/ Novartis Protocol ID CCSJ148X2202

A multicenter, randomized, patient, investigator and sponsor blinded, placebo-controlled phase II study to evaluate the efficacy and safety of CSJ148 in pregnant women with primary HCMV infection

Trial CCSJ148X2202 was cancelled with no patient enrollment and as such, no results will be reported.